BAFFR CAR-T therapy
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BAFFR CAR-T therapy, covering 2026-01-16 to 2026-02-13. Get the full timeline:
Most recent: Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]